MYELODYSPLASTIC SYNDROME
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-ada...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
2005 |
|---|
| Umfang: |
16 |
|---|
| Reproduktion: |
Annual Reviews Electronic Back Volume Collection 1932-2005ff |
|---|---|
| Übergeordnetes Werk: |
in: Annual review of medicine - Palo Alto, Calif. : Annual Reviews, 1950, 56(2005), Seite 1-16 |
| Übergeordnetes Werk: |
volume:56 ; year:2005 ; pages:1-16 ; extent:16 |
| Links: |
|---|
| Katalog-ID: |
NLEJ164130357 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ164130357 | ||
| 003 | DE-627 | ||
| 005 | 20230506101903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070207s2005 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)NLEJ164130357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a MYELODYSPLASTIC SYNDROME |
| 264 | 1 | |c 2005 | |
| 300 | |a 16 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. | ||
| 533 | |f Annual Reviews Electronic Back Volume Collection 1932-2005ff | ||
| 700 | 1 | |a Hofmann, Wolf-K. |4 oth | |
| 700 | 1 | |a Koeffler, H. Phillip |4 oth | |
| 773 | 0 | 8 | |i in |t Annual review of medicine |d Palo Alto, Calif. : Annual Reviews, 1950 |g 56(2005), Seite 1-16 |h Online-Ressource |w (DE-627)NLEJ164018786 |w (DE-600)1481484-5 |x 1545-326X |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2005 |g pages:1-16 |g extent:16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev.med.56.082103.104704 |q text/html |z Deutschlandweit zugänglich |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-ANR | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2005 |h 1-16 |g 16 | ||
| matchkey_str |
article:1545326X:2005----::yldslsi |
|---|---|
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
(DE-627)NLEJ164130357 DE-627 ger DE-627 rakwb MYELODYSPLASTIC SYNDROME 2005 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. Annual Reviews Electronic Back Volume Collection 1932-2005ff Hofmann, Wolf-K. oth Koeffler, H. Phillip oth in Annual review of medicine Palo Alto, Calif. : Annual Reviews, 1950 56(2005), Seite 1-16 Online-Ressource (DE-627)NLEJ164018786 (DE-600)1481484-5 1545-326X nnns volume:56 year:2005 pages:1-16 extent:16 http://dx.doi.org/10.1146/annurev.med.56.082103.104704 text/html Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-ANR GBV_NL_ARTICLE AR 56 2005 1-16 16 |
| spelling |
(DE-627)NLEJ164130357 DE-627 ger DE-627 rakwb MYELODYSPLASTIC SYNDROME 2005 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. Annual Reviews Electronic Back Volume Collection 1932-2005ff Hofmann, Wolf-K. oth Koeffler, H. Phillip oth in Annual review of medicine Palo Alto, Calif. : Annual Reviews, 1950 56(2005), Seite 1-16 Online-Ressource (DE-627)NLEJ164018786 (DE-600)1481484-5 1545-326X nnns volume:56 year:2005 pages:1-16 extent:16 http://dx.doi.org/10.1146/annurev.med.56.082103.104704 text/html Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-ANR GBV_NL_ARTICLE AR 56 2005 1-16 16 |
| allfields_unstemmed |
(DE-627)NLEJ164130357 DE-627 ger DE-627 rakwb MYELODYSPLASTIC SYNDROME 2005 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. Annual Reviews Electronic Back Volume Collection 1932-2005ff Hofmann, Wolf-K. oth Koeffler, H. Phillip oth in Annual review of medicine Palo Alto, Calif. : Annual Reviews, 1950 56(2005), Seite 1-16 Online-Ressource (DE-627)NLEJ164018786 (DE-600)1481484-5 1545-326X nnns volume:56 year:2005 pages:1-16 extent:16 http://dx.doi.org/10.1146/annurev.med.56.082103.104704 text/html Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-ANR GBV_NL_ARTICLE AR 56 2005 1-16 16 |
| allfieldsGer |
(DE-627)NLEJ164130357 DE-627 ger DE-627 rakwb MYELODYSPLASTIC SYNDROME 2005 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. Annual Reviews Electronic Back Volume Collection 1932-2005ff Hofmann, Wolf-K. oth Koeffler, H. Phillip oth in Annual review of medicine Palo Alto, Calif. : Annual Reviews, 1950 56(2005), Seite 1-16 Online-Ressource (DE-627)NLEJ164018786 (DE-600)1481484-5 1545-326X nnns volume:56 year:2005 pages:1-16 extent:16 http://dx.doi.org/10.1146/annurev.med.56.082103.104704 text/html Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-ANR GBV_NL_ARTICLE AR 56 2005 1-16 16 |
| allfieldsSound |
(DE-627)NLEJ164130357 DE-627 ger DE-627 rakwb MYELODYSPLASTIC SYNDROME 2005 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. Annual Reviews Electronic Back Volume Collection 1932-2005ff Hofmann, Wolf-K. oth Koeffler, H. Phillip oth in Annual review of medicine Palo Alto, Calif. : Annual Reviews, 1950 56(2005), Seite 1-16 Online-Ressource (DE-627)NLEJ164018786 (DE-600)1481484-5 1545-326X nnns volume:56 year:2005 pages:1-16 extent:16 http://dx.doi.org/10.1146/annurev.med.56.082103.104704 text/html Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-ANR GBV_NL_ARTICLE AR 56 2005 1-16 16 |
| source |
in Annual review of medicine 56(2005), Seite 1-16 volume:56 year:2005 pages:1-16 extent:16 |
| sourceStr |
in Annual review of medicine 56(2005), Seite 1-16 volume:56 year:2005 pages:1-16 extent:16 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annual review of medicine |
| authorswithroles_txt_mv |
Hofmann, Wolf-K. @@oth@@ Koeffler, H. Phillip @@oth@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ164018786 |
| id |
NLEJ164130357 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ164130357</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506101903.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070207s2005 xx |||||o 00| ||und c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ164130357</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">MYELODYSPLASTIC SYNDROME</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">16</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Annual Reviews Electronic Back Volume Collection 1932-2005ff</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofmann, Wolf-K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koeffler, H. Phillip</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annual review of medicine</subfield><subfield code="d">Palo Alto, Calif. : Annual Reviews, 1950</subfield><subfield code="g">56(2005), Seite 1-16</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ164018786</subfield><subfield code="w">(DE-600)1481484-5</subfield><subfield code="x">1545-326X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:2005</subfield><subfield code="g">pages:1-16</subfield><subfield code="g">extent:16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1146/annurev.med.56.082103.104704</subfield><subfield code="q">text/html</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-ANR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">2005</subfield><subfield code="h">1-16</subfield><subfield code="g">16</subfield></datafield></record></collection>
|
| series2 |
Annual Reviews Electronic Back Volume Collection 1932-2005ff |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ164018786 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1545-326X |
| topic_title |
MYELODYSPLASTIC SYNDROME |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
w k h wkh h p k hp hpk |
| hierarchy_parent_title |
Annual review of medicine |
| hierarchy_parent_id |
NLEJ164018786 |
| hierarchy_top_title |
Annual review of medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ164018786 (DE-600)1481484-5 |
| title |
MYELODYSPLASTIC SYNDROME |
| spellingShingle |
MYELODYSPLASTIC SYNDROME |
| ctrlnum |
(DE-627)NLEJ164130357 |
| title_full |
MYELODYSPLASTIC SYNDROME |
| journal |
Annual review of medicine |
| journalStr |
Annual review of medicine |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
1 |
| container_volume |
56 |
| physical |
16 |
| format_se |
Elektronische Aufsätze |
| title_sort |
myelodysplastic syndrome |
| title_auth |
MYELODYSPLASTIC SYNDROME |
| abstract |
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. |
| abstractGer |
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. |
| abstract_unstemmed |
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS. |
| collection_details |
GBV_USEFLAG_U ZDB-1-ANR GBV_NL_ARTICLE |
| title_short |
MYELODYSPLASTIC SYNDROME |
| url |
http://dx.doi.org/10.1146/annurev.med.56.082103.104704 |
| remote_bool |
true |
| author2 |
Hofmann, Wolf-K. Koeffler, H. Phillip |
| author2Str |
Hofmann, Wolf-K. Koeffler, H. Phillip |
| ppnlink |
NLEJ164018786 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| up_date |
2024-07-06T10:11:24.496Z |
| _version_ |
1803824067506077696 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ164130357</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506101903.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070207s2005 xx |||||o 00| ||und c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ164130357</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">MYELODYSPLASTIC SYNDROME</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">16</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Annual Reviews Electronic Back Volume Collection 1932-2005ff</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofmann, Wolf-K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koeffler, H. Phillip</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annual review of medicine</subfield><subfield code="d">Palo Alto, Calif. : Annual Reviews, 1950</subfield><subfield code="g">56(2005), Seite 1-16</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ164018786</subfield><subfield code="w">(DE-600)1481484-5</subfield><subfield code="x">1545-326X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:56</subfield><subfield code="g">year:2005</subfield><subfield code="g">pages:1-16</subfield><subfield code="g">extent:16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1146/annurev.med.56.082103.104704</subfield><subfield code="q">text/html</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-ANR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">56</subfield><subfield code="j">2005</subfield><subfield code="h">1-16</subfield><subfield code="g">16</subfield></datafield></record></collection>
|
| score |
7.4000244 |